Molecular diagnostics supernova on board at Congenica
One of the world’s most pre-eminent molecular diagnostics specialists has boosted the board of Cambridge digital health company Congenica.
Dr Heiner Dreismann has accepted roles as non-executive director and senior independent director. He has over 35 years’ experience in the global leadership of high-growth life sciences and healthcare businesses.
Dr Dreismann was previously president and CEO of Roche Molecular Systems, the world leader in molecular diagnostics, where he made significant contributions to the organisational and financial growth of the company’s molecular business area.
Other senior positions he held in Roche included head of global business development, Roche Diagnostics and member of Roche’s global diagnostic executive committee.
Since leaving Roche he has served on the board of a number of private and public biotech and healthcare companies.
Dr Dreismann said: “I am excited to join the board of Congenica, a company at the forefront of healthcare innovation that is bringing medical meaning to genomic data.
“I look forward to helping the company in its next stage of growth and in supporting healthcare professionals with its technologies to expedite the diagnosis and treatment of conditions affecting millions of people worldwide.”
Congenica enables genomic medicine with what it markets as the world’s leading clinical decision support platform for the interpretation of complex genomic data.